Cardiac surgery patients are often exposed to blood products perioperatively (18). Due to their underlying cardiac condition and ventricular dysfunction these patients are at an increased risk for TACO.(19) In a *proof of principle* approach we will…
ID
Source
Brief title
Condition
- Heart failures
- Pulmonary vascular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Hydrostatic pressure overload defined as * PCWP
Secondary outcome
Capillary leakage defined as * EVLWI
Volume overload measured by
Pulmonary artery catheter CO
Arterial line / PICCO MAP, PPV, SVV, CO, CI, EVLWI, SVR
Colloid osmotic pressure COP
by membrane colloid osmometer
Estimated circulating volume * PV, * BV
Microcirculation measured by
CytoCam microscope system TVD, PVD, PPV, MFI, Øbv
Fluid responsiveness defined by PLR * CO > 10%
TACO criteria 6 hours after infusion of autologous blood transfusion
Background summary
Transfusion associated cardiac overload (TACO) is now considered the leading
cause of transfusion*related mortality in Europe. TACO is defined in terms of
clinical characteristics. The International Society of Blood Transfusion
defined TACO as the onset of any four of the following symptoms which occur
within six hours of transfusion: acute respiratory distress, tachycardia,
increased blood pressure, acute or worsening pulmonary edema and or evidence of
positive fluid balance. Other definitions use similar markers such as bilateral
infiltrates, ultrasound of the heart, pulmonary wedge pressure or a history of
cardiac decompensation.
The pathophysiology of TACO is poorly understood; current literature describes
TACO as hydrostatic pulmonary edema due to volume overload. This seems
unlikely, since 20% of TACO occurs after only one transfused unit. Moreover,
differences in the incidences of TACO after red blood cell (RBC) compared to
plasma transfusion cannot be explained. Our hypothesis is that the pathogenesis
is a *two hit**entity: the *first hit* is an underlying condition (e.g. cardiac
failure or acute kidney injury) resulting in poor compliance to fluid loading *
the *second hit* being a transfusion. This may explain why especially
critically ill patients are at risk. Furthermore, we hypothesize that TACO is a
combination of hydrostatic pulmonary edema (overload) and pulmonary edema by
protein leakage following exposure to mediators in different types of blood
products (a mechanism similar to transfusion related acute lung injury).
It is paramount to understand the pathophysiology of TACO, as currently no
evidence-based therapy exists for this life-threatening syndrome.
Study objective
Cardiac surgery patients are often exposed to blood products perioperatively
(18). Due to their underlying cardiac condition and ventricular dysfunction
these patients are at an increased risk for TACO.(19) In a *proof of principle*
approach we will determine whether TACO is solely volume overload or arises
from a combination of volume overload and capillary leakage, by investigating
the difference in change in volume parameters and capillary leakage after
autologous transfusion or saline infusion. Furthermore, we will investigate the
effect of fluid loading on the microcirculation.
Study design
Open-label, prospective cross-over randomized controlled trial.
Intervention
Patients will be allocated to either infusion of 300mL saline with a subsequent
autologous RBC (cell saver) transfusion of 300 mL at a rate of 10mL/min, or the
same in the reversed order. Prior to start of the intervention, 15 minutes
following start of infusion and a the end of infusion, we will measure wedge
pressure (PCWP), as well as extravascular lung water index (EVLWI) and CO
estimation through PICCO® and Pulmonary Artery Catheter. We will identify fluid
responsiveness by performing a passive leg raise test (PLR). We aim to measure
total vessel density (TVD), perfused vessel density (PVD), proportion of
perfused vessels (PPV), microvascular flow index (MFI), and blood vessel
diameters (Øbv) from the oral microcirculation by CytoCam microscope system. We
will estimate the effective circulating blood and plasma volume through
dilutional infusion of indocyanine green prior to initial infusion, between and
at the end of subsequent infusion. In total 6 times measurements will be
performed.
Study burden and risks
The study provides no benefits for the participants. The study will include
placement of a Swan Ganz catheter. Central line placement is part of standard
care in cardiac surgery. The placement of a Swan Ganz Catheter depends on
patient category, anaesthesiologist and hospital settings. The application of a
Swan Ganz Catheter may result in a better read out of cardiac function. On the
other hand, some studies find a small increase in catheter related side
effects.
Meibergdreef 9
Amsterdam 1105AZ
NL
Meibergdreef 9
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
1. Age >18 years
2. Elective (non-redo) coronary arterial bypass grafting surgery
3. Reduced left ventricular ejection fraction (<55%)
4. Transfusion of autologous blood (cell saver blood, 300ml, HCT60%, 30min)
5. Informed consent
Exclusion criteria
1. Patients with no indication for autologous RBC transfusion
2. Patients with pulmonary hypertension, congenital heart disease, mitral or tricuspid valve disease.
3. Contraindications for PAC placement; coagulopathy, bundle branch block, defibrillator or pacemaker (risk of displacement). External pacemaker placed during surgery is no exclusion criterium.
4. Patients for acute, non-elective surgery
5. Chronic kidney disease stage 4 or higher (eGFR < 30)
6. Massive transfusion
7. Previous randomization in the current trial
8. Postoperative ongoing bleeding
9. Bypass duration > 2 hours
10. Infusion of high dose corticosteroids
11. Hemodynamic instability with a mean arterial pressure (MAP) < 60 mmHg, central venous pressure > 20 mmHg or dependence on high dosages of inotropic drugs after admittance to the ICU
12. Severe arrhythmias
13. Development of severe pulmonary edema during infusion of autologous blood or saline.
14. Elevated liver enzymes
15. Iodine allergy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL59191.018.16 |